Intravitreal Ranibizumab in Combination with Verteporfin Photodynamic Therapy in Neovascular Macular Degeneration
Authors:
P. Souček; I. Součková
Authors‘ workplace:
Oftalmologická klinika FNKV, Praha, přednosta prof. MUDr. Pavel Kuchynka, CSc.
Published in:
Čes. a slov. Oftal., 64, 2008, No. 4, p. 135-140
Overview
Purpose:
To evaluate safety and efficacy of intravitreal ranibizumab (IVR) combined with verteporfin photodynamic therapy (PDT) in neovascular macular degeneration.
Methods:
Ten eyes of ten patients received one IVR 0.5 mg after verteporfin PDT (standard regimen), then the treatment has been indicated PRN (pro re nata; when necessary). Patients were examined to exclude acute disease, which could prevent to initiate the treatment. Eyes were evaluated, with ETDRS the best-corrected visual acuity (BCVA), intraocular pressure, and slit lamp and after pupil dilatation biomicroscopy and optical coherence tomography (OCT) at baseline and monthly thereafter. Fluorescein angiography (FA) was performed at baseline and after three months.
In the study group, there were two cases (20%) of new idiopathic choroidal neovascularization and 8 patients (80%) who were previously treated at least once by verteporfin due to age-related macular degeneration.
Another session of IVR would be performed in case of 5-letter decrease of BCVA, 100-μm increase of central retinal thickness (CRT) or new hemorrhages in the macula. Next verteporfin PDT therapy would be indicated in case of a leakage on FA. The mean BCVA before the treatment was of 0.3, CRT of 228 μm and macular volume of 6.79 mm³. The mean follow-up was 3.5 months.
Results:
There were no BCVA decrease, OCT increase bigger than stated above or new hemorrhages at any visit (n=25). There was no leakage on any FA at month 3 (n=10). That is why only one session of combined verteporfin PDT and IVR was performed in all patients (100 %). The mean BCVA improved to 0.5 (mean increase by 13.5 letters), CRT dropped to 198 μm and macular volume to 6.33 mm³. No systemic or ocular side effects were noted.
Conclusion:
Longer follow-up and larger study group are mandatory to confirm early positive results of this therapy (improvement by 13.5 letters after one session of combination of verteporfin PDT and RIV) which seems to be the most promising due to absence of serious complications with smoother disease management and lower financial burden.
Key words:
verteporfin, ranibizumab, neovascular macular degeneration, choroidal neovascularization, optical coherence tomography, fluorescein angiography
Sources
1. Augustin, AJ., Offerman, I.: Combination therapy for choroidal neovascularization, Drugs Aging, 24, 2007: 979–990
2. Brown, DM., Kaiser, PK., Michels, M. et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, 355, 2006: 1432-1444
3. Cihelková, I., Souček, P.: Nálezy na optické koherentní tomografii u pacientů s makulární degenerací léčených pomocí fotodynamické terapie s preparátem Visudyne. Čes. a slov. Oftal, 59, 2003: 250–256
4. Cihelková, I., Souček, P.: Atlas makulárních chorob/Atlas of macular diseases, Praha, Galén/Karolinum, 2005, 521 s.
5. DENALI Study Group: SUMMIT: Combination Therapy With Verteporfin PDT and Ranibizumab for Subfoveal Choroidal Neovascularization Due to AMD, Invest Ophthalmol Vis Sci, 48, 2007: ARVO E-Abstract 1817
6. Fung, AE., Lalwani, GA., Rosenfeld, PJ. et al.: An Optical Coherence Tomography-Guided, Variable Dosing Regiment with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration, Am J Ophthalmol, 143, 2007: 566–583
7. Jabbour, NM., Odom, JV.: Comparison of Treatment Using Intravitreal Ranibizumab Alone With Combination Treatment Using Intravitreal Ranibizumab and Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration, , 2008: poster 560/A528
8. Kaiser, PK., Brown, DM., Zhang, K. et al.: Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results, Am J Ophthalmol, 144, 2007: 850–857
9. Karel I.: Možnosti a ekonomické ukazatele léčby exsudativní věkem podmíněné makulární degenerace s choroidální neovaskulární membranous, Čes. a slov. Oftal, 63, 2007: 311‑319
10. Kim, IK., Husain, D., Michaud, N.: Effect of Intravitreal Injection of Ranibizumab in Combination with Verteporfin PDT on Normal Primate Retina and Choroid, Invest Ophthalmol Vis Sci, 47, 2006: 357-363
11. Meyer, CH., Eter, N., Holz, FG.: Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Interim Results From the SUSTAIN Trial, , 2008: poster 273/A582
12. Regillo, CD., Brown, DM., Abraham, P. et al.: Randomized, Double Maskér, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1, Am J Ophthalmol, 145, 2008: 239-248
13. Schmidt-Erfurth, UM., Richard, G., Augustin, A. et al.: Guidance for the treatment of neovacular age-related macular degeneration, Acta Ophthalmol Scand, 85, 2007: 486-494
14. Shah, AR., Del Priore, LV.: Duration of Action of Intravitreal Ranibizumab and Bevacizumab in Exudative AMD Based on Macular Volume Measurements, , 2008: poster 305/D626
15. Souček, P., Boguzsaková, J., Cihelková, I.: Fotodynamická terapie s preparátem Visudyne u makulární degenerace se subfoveolárně uloženou převážně klasickou choroidální neovaskularizací, Čes a Slov Oftal, 58, 2002: 89-97
16. Souček, P., Cihelková, I.: Treatment of macular degeneration, a controlled case, Neuroendocrinol Lett, 23, 2002: 370-372
17. Souček, P., Cihelková, I.: Photodynamic therapy with verteporfin in predominantly classic subfoveal CNV in age-related and myopic macular degeneration. In Ioseliani (Ed.), Focus on Macular Degeneration Research, New York, Nova Publishers, 2004, p. 241-252
18. Souček, P., Cihelková, I.: Fotodynamická terapie s verteporfinem u převážně klasické subfoveolární choroidální neovaskularizace – řešení akutních forem makulární degenerace. In Rozsíval, P. (Ed.), Trendy soudobé oftalmologie, III. svazek, Praha, Galén, 2006, s. 197-217
19. Souček, P., Cihelková I.: Fotodynamická terapie v éře anti-VEGF, Farmakoterapie, 3, 2007: 523-527
20. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clnical trials with an open-label extension – TAP Report No. 8, Graefes Arch Clin Exp Ophthalmol, 244, 2006: 1132-1142
21. Virgili, G., Do, DV., Bressler, NM. et al.: New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence, Acta Ophthalmol Scand, 85, 2007: 6-20
22. Wolf, S.: Nine Month Exploratory Endpoint Results From an Open-Label, Multicenter, Phase II Study of Same-Day Verteporfin and Ranibizumab 0.5mg (PROTECT Study), as Measured Using Optical Coherence Tomography, Fundus Photography and Fluorescein Angiography, Invest Ophthalmol Vis Sci, 48, 2007: ARVO E-Abstract 2871
23. Zuluaga, MF., Mailhos, C., Robinson, G. et al.: Synergies of VEGF Inhibition and Photodynamic Therapy in the Treatment of Age-Related Macular degeneration, Invest Ophthalmol Vis Sci, 48, 2007: 1767-1772
Labels
OphthalmologyArticle was published in
Czech and Slovak Ophthalmology
2008 Issue 4
Most read in this issue
- Anterior Transposition or Myectomy of the Inferior Oblique Muscle in Vertical Deviation – Long Term Results
- Immunohistochemical Detection of the Gene p53 and p21 Expression in Cells of the Malignant Melanoma of the Uvea
- Intravitreal Ranibizumab in Combination with Verteporfin Photodynamic Therapy in Neovascular Macular Degeneration
- Visual Functions in Premature Children after Posthemorrhagic Hydrocephalus Surgery